CWRU-licensed NervGen Pharma floated at the top of its range on the TSX Venture Exchange, with the proceeds earmarked to push its lead candidate for spinal cord injury into the clinic.

NervGen Pharma, a Canada-based developer of nerve damage therapies based on Case Western Reserve University (CWRU) research, has completed an initial public offering (IPO) which raised gross proceeds of C$10m ($7.5m). NervGen commended trading on Canada’s TSX Venture Exchange on March 15 after issuing 10 million common shares priced at C$1 ($750,000) each, bringing the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.